These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21604602)

  • 1. [Persistence in focus. Atazanavir proves itself anew in long-term therapy].
    Warpakowski A
    MMW Fortschr Med; 2011 May; 153(18):60-1. PubMed ID: 21604602
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
    Fabbiani M; Bracciale L; Doino M; D'Avino A; Marzocchetti A; Navarra P; Cauda R; De Luca A; Di Giambenedetto S
    J Infect; 2011 Apr; 62(4):319-21. PubMed ID: 21329725
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
    Warpakowski A
    MMW Fortschr Med; 2011 May; 153(18):50-1. PubMed ID: 21604599
    [No Abstract]   [Full Text] [Related]  

  • 4. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 5. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
    Puls RL; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe C; Belloso WH; Molina JM; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S;
    Clin Infect Dis; 2010 Oct; 51(7):855-64. PubMed ID: 20735258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy.
    Lê MP; Stitou H; Soulie C; Katlama C; Peytavin G
    J Antimicrob Chemother; 2013 Mar; 68(3):727-9. PubMed ID: 23118148
    [No Abstract]   [Full Text] [Related]  

  • 7. Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient.
    Courbon E; Laylavoix F; Soulié C; Le Beller C; Calvez V; Katlama C; Peytavin G
    J Antimicrob Chemother; 2012 Jan; 67(1):250-1. PubMed ID: 22025582
    [No Abstract]   [Full Text] [Related]  

  • 8. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse effects of atazanavir].
    Palacios R; González M; Ruiz J; Santos J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():41-4. PubMed ID: 20116616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 12. [Progress toward a once daily regimen. (HA)ART--the art of antiretroviral therapy].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():78-9. PubMed ID: 11373790
    [No Abstract]   [Full Text] [Related]  

  • 13. Complicated atazanavir-associated cholelithiasis: a report of 14 cases.
    Rakotondravelo S; Poinsignon Y; Borsa-Lebas F; de la Blanchardière A; Michau C; Jantzem H; Massy N; Polard E; Giroux F; Kerspern H; Meskar A; Hue G; Tribut O; Arvieux C; Tattevin P
    Clin Infect Dis; 2012 Nov; 55(9):1270-2. PubMed ID: 22820540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S; Hernández B; Dronda F
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
    Jemsek JG; Arathoon E; Arlotti M; Perez C; Sosa N; Pokrovskiy V; Thiry A; Soccodato M; Noor MA; Giordano M
    Clin Infect Dis; 2006 Jan; 42(2):273-80. PubMed ID: 16355341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA notifications. Reyataz is approved for HIV treatment.
    AIDS Alert; 2003 Sep; 18(9):119-20. PubMed ID: 14686309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():14-5. PubMed ID: 15011577
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy of atazanavir in simplification regimens].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.